



CERBA HEALTHCARE AND METAFORA BIOSYSTEMS ANNOUNCE THE SIGNING OF A PARTNERSHIP

Saint-Ouen l'Aumône and Evry, France – Monday, 7 November 2016

The Cerba HealthCare Group and METAFORA biosystems are to cooperate in the deployment of METAFORA proprietary technology in the field of metabolomics for diagnostics purposes. The technological platform developed by METAFORA enables the evaluation of cells' energy needs in connection with patients' health.

“The investigation into altered metabolic functions for the prevention and detection of disease is a field of major importance, and the availability of new tools such as METAFORA biomarkers is a real asset in the development of new diagnostic tests”, commented Jérôme Sallette, Innovation and Development Director for Cerba HealthCare Group.

The monitoring of normal and altered metabolic functions will provide new knowledge on numerous pathologies, including rare diseases, obesity, diabetes and forms of cancer. It will also enable new tests to be developed to improve the prevention of certain diseases and the maintenance of health through this biological measure.

“We are proud to be working with Cerba HealthCare to contribute to the development of diagnostics solutions in the field of metabolism. Thanks to its scientific excellence and the Group's vast network of laboratories and health professionals, we are confident that this partnership will help us bring our innovative tests to market under the best conditions”, said Vincent Petit, co-founder and CEO of METAFORA biosystems.

About METAFORA biosystems

METAFORA biosystems was established in 2011, and is based at Genopole®, Evry, France. The company is developing an innovative technology, the only one able to assess cells' nutrition needs simply and quickly, therefore assessing and detecting anomalies in their energy needs.

Proprietary reagents (RBDs) and cutting-edge algorithms are at the heart of the technology platform, and enable “metabolic reprogramming”, induced during numerous pathological processes, to be detected.

RBD applications have been approved in numerous scientific articles published in leading reviews, and METAFORA now deploys its technology for in-vitro diagnostics (IVD). The launch of the first test on the market is at a very advanced stage, and developments are already in progress to position the platform on cancer, inflammatory diseases and metabolic diseases markets, as much applications that will make METAFORA a key player in diagnostics.

<http://www.metafora-biosystems.com>

About CERBA HEALTHCARE

The Group has a presence in three complementary segments:

- routine medical biology, mainly in France, Belgium and Luxembourg, with more than 300 laboratories, 150 specimen collection centres and 50 technical platforms.
- specialty medical biology, through its historic laboratory serving more than 50 countries in Europe, Africa and Asia.
- clinical trial biology, essential in the processes of developing new molecules for the pharmaceutical and biotechnology industry, through its subsidiaries located across five continents.

Recently the Group diversified in the veterinary biology market by creating Cerba Vet, a dedicated entity.

It has almost 4,300 employees including 350 biologists. In 2015, its consolidated turnover was € 605 million.

<http://www.cerbahealthcare.com>

Contacts

Vincent Petit

CEO METAFORA biosystems

vincent.petit@metafora-biosystems.com | www.metafora-biosystems.com

Jérôme Sallette

Innovation and Development Director

CERBA HEALTHCARE

jerome.sallette@cerbahealthcare.com | www.cerbahealthcare.com